Pacific - Chronic Kidney Disease+Hypertension

  • Study Sponsor and Protocol Number: 
    AstraZeneca / D6972C00002 – PACIFIC
  • Specialty:
    Nephrology
  • Type:
    Investigational Drug in combination with a known medication (Dapagliflozin)
  • Inclusion:
    Hypertension
    eGFR between 30-75
    Urine albumin creatinine ratio between 30 and 5000 (range dependent on eGRF value)
  • Exclusion:
    Type 1 Diabetes
    Class 4 Heart Failure
    Hyperkalaemia